Viracta Therapeutics' Phase 2 Nana-val Trial Shows Robust Results in Second-Line Subgroup; Shares Rise Pre-Bell

MT Newswires Live08-14

Viracta Therapeutics (VIRX) said Wednesday that new data from a phase 2 trial evaluating drug combination Nana-val showed robust antitumor activity in a second-line subgroup, which it will focus based on feedback from the US Food and Drug Administration for potential approval.

Nana-val is a combination of nanatinostat, a selective treatment for Epstein-Barr virus, and antiviral medication valganciclovir. Viracta is investigating Nana-val for the treatment of EBV-associated malignancies.

The second-line subgroup of the phase 2 trial showed overall response rates of at least 60% and complete response rates of over 30% in both populations. Viracta said it will focus its primary analysis on this subgroup for the ongoing trial.

The company also plans to begin a new randomized controlled trial of Nana-val in the second-line subgroup in 2025, saying this strategy will give way for accelerated approval after filing in 2026.

Shares of Viracta rose more than 27% in recent premarket activity Wednesday.

Price: 0.6000, Change: +0.13, Percent Change: +27.69

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2459175812?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-14 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2459175812","market":"hk","top_or_hot":-1,"title":"Viracta Therapeutics' Phase 2 Nana-val Trial Shows Robust Results in Second-Line Subgroup; Shares Rise Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Viracta <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VIRX) said Wednesday that new data from a phase 2 trial evaluating drug combination Nana-val showed robust antitumor activity in a second-line subgroup, which it will focus based on feedback from the US Food and Drug Administration for potential approval.</p><p>Nana-val is a combination of nanatinostat, a selective treatment for Epstein-Barr virus, and antiviral medication valganciclovir. Viracta is investigating Nana-val for the treatment of EBV-associated malignancies.</p><p>The second-line subgroup of the phase 2 trial showed overall response rates of at least 60% and complete response rates of over 30% in both populations. Viracta said it will focus its primary analysis on this subgroup for the ongoing trial.</p><p>The company also plans to begin a new randomized controlled trial of Nana-val in the second-line subgroup in 2025, saying this strategy will give way for accelerated approval after filing in 2026.</p><p>Shares of Viracta rose more than 27% in recent premarket activity Wednesday.</p><p>Price: 0.6000, Change: +0.13, Percent Change: +27.69</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viracta Therapeutics' Phase 2 Nana-val Trial Shows Robust Results in Second-Line Subgroup; Shares Rise Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViracta Therapeutics' Phase 2 Nana-val Trial Shows Robust Results in Second-Line Subgroup; Shares Rise Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-14 20:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Viracta Therapeutics (VIRX) said Wednesday that new data from a phase 2 trial evaluating drug combination Nana-val showed robust antitumor activity in a second-line subgroup, which it will focus based...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2459175812","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2459175812","pubTimestamp":1723639029,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Viracta Therapeutics  said Wednesday that new data from a phase 2 trial evaluating drug combination Nana-val showed robust antitumor activity in a second-line subgroup, which it will focus based on feedback from the US Food and Drug Administration for potential approval.Nana-val is a combination of nanatinostat, a selective treatment for Epstein-Barr virus, and antiviral medication valganciclovir. Viracta is investigating Nana-val for the treatment of EBV-associated malignancies.The second-line subgroup of the phase 2 trial showed overall response rates of at least 60% and complete response rates of over 30% in both populations. Viracta said it will focus its primary analysis on this subgroup for the ongoing trial.The company also plans to begin a new randomized controlled trial of Nana-val in the second-line subgroup in 2025, saying this strategy will give way for accelerated approval after filing in 2026.Shares of Viracta rose more than 27% in recent premarket activity Wednesday.Pric","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","VIRX":"Viracta Therapeutics, Inc."},"translate_title":"Viracta Therapeutics的2期Nana-val试验在二线亚组中显示出强劲的结果；盘前股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"VIRX":0.9},"content_text":"Viracta Therapeutics (VIRX) said Wednesday that new data from a phase 2 trial evaluating drug combination Nana-val showed robust antitumor activity in a second-line subgroup, which it will focus based on feedback from the US Food and Drug Administration for potential approval.Nana-val is a combination of nanatinostat, a selective treatment for Epstein-Barr virus, and antiviral medication valganciclovir. Viracta is investigating Nana-val for the treatment of EBV-associated malignancies.The second-line subgroup of the phase 2 trial showed overall response rates of at least 60% and complete response rates of over 30% in both populations. Viracta said it will focus its primary analysis on this subgroup for the ongoing trial.The company also plans to begin a new randomized controlled trial of Nana-val in the second-line subgroup in 2025, saying this strategy will give way for accelerated approval after filing in 2026.Shares of Viracta rose more than 27% in recent premarket activity Wednesday.Price: 0.6000, Change: +0.13, Percent Change: +27.69","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459175812"}